Maxim Group Increases Capricor Therapeutics (NASDAQ:CAPR) Price Target to $25.00

Capricor Therapeutics (NASDAQ:CAPR) had its price objective raised by investment analysts at Maxim Group from $12.00 to $25.00 in a report issued on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Maxim Group’s target price points to a potential upside of 174.73% from the stock’s current price.

Other equities analysts have also recently issued reports about the company. Oppenheimer reissued an “outperform” rating and set a $15.00 target price on shares of Capricor Therapeutics in a research note on Monday. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of Capricor Therapeutics in a research note on Tuesday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $8.00 price target on shares of Capricor Therapeutics in a research note on Friday, September 20th. One analyst has rated the stock with a sell rating and five have given a buy rating to the company. According to MarketBeat, Capricor Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.60.

Capricor Therapeutics Stock Performance

Shares of CAPR stock opened at $9.10 on Wednesday. Capricor Therapeutics has a fifty-two week low of $2.68 and a fifty-two week high of $9.24. The stock has a 50 day moving average price of $4.48 and a two-hundred day moving average price of $5.21. The company has a market capitalization of $296.11 million, a P/E ratio of -10.46 and a beta of 3.92.

Capricor Therapeutics (NASDAQ:CAPR) last posted its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.03). Capricor Therapeutics had a negative net margin of 102.93% and a negative return on equity of 220.27%. The business had revenue of $3.97 million for the quarter, compared to analysts’ expectations of $4.51 million. As a group, equities analysts predict that Capricor Therapeutics will post -1.14 earnings per share for the current year.

Insider Transactions at Capricor Therapeutics

In related news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of the business’s stock in a transaction dated Friday, September 20th. The shares were purchased at an average cost of $5.36 per share, with a total value of $14,999,997.52. Following the completion of the purchase, the insider now owns 7,090,351 shares in the company, valued at approximately $38,004,281.36. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 12.00% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in shares of Capricor Therapeutics by 17.2% during the first quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock valued at $9,274,000 after purchasing an additional 200,499 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Capricor Therapeutics by 158.7% during the second quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock valued at $656,000 after purchasing an additional 84,350 shares in the last quarter. Marshall Wace LLP bought a new position in shares of Capricor Therapeutics during the second quarter valued at $426,000. Bank of New York Mellon Corp lifted its holdings in shares of Capricor Therapeutics by 12.8% during the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock valued at $381,000 after purchasing an additional 9,040 shares in the last quarter. Finally, Rhumbline Advisers bought a new position in shares of Capricor Therapeutics during the second quarter valued at $147,000. 21.68% of the stock is owned by institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.